

Weekly COVID-19 Breakthrough Infections Report

Clark County, Nevada

Date: January 10, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.





Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations








Table 1: Population Characteristics of COVID-19 Breakthrough Cases

	Overa	
	N	%
All	128383 1	100
Age (in years)		
0-4	4	0
5-11	1548	1
12-17	5928	5
18-24	10996	9
25-49	56165	44
50-64	30551	24
65+	23191	18
Gender		
Male	55942	44
Female	71473	56
Unknown	968	1
Race/Ethnicity		
Hispanic	26357	21
White	40733	32
Black	10033	8
API	16343	13
AEA	443	0
Other	9189	7
Unknown	25285	20
Travel History		
Yes	5492	4
No	34457	
Unknown	88434	
Hospitalization	00.01	00
Yes	3243	3
No	38866	
Unknown	86274	67
Death	00274	01
Yes	1174	1
No	9632	8
· .	117577	
Unknown	11/3//	92
Vaccine Type	05044	67
Pfizer	85841	67
Novavax	5	0
Unknown	1090	1
Moderna	34446	27
Janssen	7000	5
Emergen	1	0
Underlying Conditions		
Yes	19116	15
No	109267	85

Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
860057	128383	1458117	467002	14927	32028



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations

	Ove	Overall	
	Ν	%	
All	3243	100	
Age (in years)			
5-11	5	0	
12-17	18	1	
18-24	31	1	
25-49	333	10	
50-64	563	17	
65+	2293	71	
Gender			
Male	1760	54	
Female	1479	46	
Unknown	4	0	
Race/Ethnicity			
Hispanic	402	12	
White	1884	58	
Black	367	11	
API	319	10	
AEA	15	0	
Other	99	3	
Unknown	157	5	
Travel History			
Yes	140	4	
No	1678	52	
Unknown	1425	44	
Death			
Yes	822	25	
No	578	18	
Unknown	1843	57	
Vaccine Type			
Pfizer	1890	58	
Unknown	80	2	
Moderna	1032	32	
Janssen	241	7	
Underlying Conditions			
Yes	2343	72	
No	900	28	



Table 4:Population Characteristics of COVID-19 Breakthrough Deaths

	Ove	Overall	
	Ν	%	
All	1174	100	
Age (in years)	-		
25-49	37	3	
50-64	140	12	
65+	997	85	
Gender			
Male	707	60	
Female	467	40	
Race/Ethnicity			
Hispanic	130	11	
White	790	67	
Black	121	10	
API	113	10	
AEA	6	1	
Other	10	1	
Unknown	4	0	
Hospitalization			
Yes	822	70	
No	76	6	
Unknown	276	24	
Vaccine Type			
Pfizer	647	55	
Unknown	27	2	
Moderna	380	32	
Janssen	120	10	
Underlying Conditions			
Yes	672	57	
No	502	43	

Table 5: Breakthrough Death Rates

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
860057	1174	1458117	8065	137	553

^{*} Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson salanssen vaccine.



Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	2343	72
	No	900	28
Hypertension	Yes	1497	N/A
Immunocompromised	Yes	131	N/A
Chronic Heart Disease	Yes	710	N/A
Chronic Liver Disease	Yes	62	N/A
Chronic Kidney Disease	Yes	466	N/A
Diabetes	Yes	876	N/A
Neurologic/Neurodevelopmental	Yes	197	N/A
Chronic Lung Disease	Yes	618	N/A
Historically Healthy	Yes	285	N/A

Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	N	%
Underlying Medical Condition	Yes	672	57
	No	502	43
Hypertension	Yes	432	N/A
Immunocompromised	Yes	48	N/A
Chronic Heart Disease	Yes	242	N/A
Chronic Liver Disease	Yes	24	N/A
Chronic Kidney Disease	Yes	187	N/A
Diabetes	Yes	256	N/A
Neurologic/Neurodevelopmental	Yes	59	N/A
Chronic Lung Disease	Yes	195	N/A
Historically Healthy	Yes	27	N/A

Notes:

^{*} White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

^{*} The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

^{*} The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).